Search

Your search keyword '"Agmon-Levin, N."' showing total 395 results

Search Constraints

Start Over You searched for: Author "Agmon-Levin, N." Remove constraint Author: "Agmon-Levin, N."
Sorry, I don't understand your search. ×
395 results on '"Agmon-Levin, N."'

Search Results

1. Résultats de phase 2 d’efficacité et de tolérance jusqu’à 52 semaines du ianalumab, anti-BAFF récepteur (BAFF-R), chez les patients atteints de lupus érythémateux systémique (LES)

3. Efficacité des thérapies ciblant les éosinophiles chez les patients atteints de granulomatose éosinophilique avec polyangéite en fonction du statut des ANCA : analyse post-hoc de l’étude de phase 3 MANDARA

4. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials

5. Résultats de phase 2 d'efficacité et de tolérance jusqu'à 52 semaines de l'ianalumab, anti-BAFF récepteur (BAFF-R), chez les patients atteints de lupus érythémateux systémique (LES).

6. POS0120 SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED MONTHLY OVER 28 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

15. EULAR recommendations for womenʼs health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome

18. Vaccination in adult patients with auto-immune inflammatory rheumatic diseases: A systematic literature review for the European League Against Rheumatism evidence-based recommendations for vaccination in adult patients with auto-immune inflammatory rheumatic diseases

19. POS1254 RISK FACTORS FOR SEVERE COVID-19 INFECTION AMONG PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES (AIRD) AND THE IMPACT OF VACCINATIONS - AN ISRAELI, MULTI-CENTER EXPERIENCE

21. Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants

25. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria

26. POS1217 THE PATTERN OF COVID 19 PANDEMIC AMONG PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES (AIIRD)

33. The interaction between anti-Ro/SSA and anti-La/SSB autoantibodies and anti-infectious antibodies in a wide spectrum of auto-immune diseases: another angle of the autoimmune mosaic

36. 慢性荨麻疹和骨质疏松

37. Chronic urticaria and osteoporosis

38. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome

39. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials

43. SAFETY AND EFFICACY OF SUBCUTANEOUS (S.C.) DOSE IANALUMAB (VAY736; ANTI-BAFFR mAb) ADMINISTERED MONTHLY OVER 28 WEEKS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE).

44. Circulating microRNAs in Sera Correlate with Soluble Biomarkers of Immune Activation but Do Not Predict Mortality in ART Treated Individuals with HIV-1 Infection: A Case Control Study

45. Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study

46. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome

47. THU0304 Adherence To Hydroxychloroquine as Assessed by Measurements of Drug and Metabolite Blood Levels in An International Prospective Study of Sle Patients in Flare

48. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies

50. Hydroxychloroquine desensitization, an effective method to overcome hypersensitivity--a multicenter experience.

Catalog

Books, media, physical & digital resources